Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 8000.00 SEK | -97.27% |
| 2022 | 293 Thousand SEK | 70363.79% |
| 2021 | -417.00 SEK | -100.09% |
| 2020 | 442.98 Thousand SEK | 0.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -450.01 Thousand SEK | 57.11% |
| 2017 | -1.04 Million SEK | -132.86% |
| 2016 | -450.56 Thousand SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.23 Million SEK | 15337.5% |
| 2024 Q2 | 1.23 Million SEK | 0.0% |
| 2023 Q3 | 8000.00 SEK | 214748364799900.0% |
| 2023 Q4 | 8000.00 SEK | 0.0% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2023 FY | 8000.00 SEK | -97.27% |
| 2022 Q4 | 293 Thousand SEK | 29299900.0% |
| 2022 Q3 | 1.00 SEK | 100.0% |
| 2022 Q2 | -2.35 Million SEK | 0.0% |
| 2022 Q1 | - SEK | 100.0% |
| 2022 FY | 293 Thousand SEK | 70363.79% |
| 2021 Q1 | 493 Thousand SEK | 11.29% |
| 2021 Q3 | - SEK | -100.0% |
| 2021 FY | -417.00 SEK | -100.09% |
| 2021 Q4 | -417.00 SEK | 0.0% |
| 2021 Q2 | 493 Thousand SEK | 0.0% |
| 2020 Q4 | 442.98 Thousand SEK | -0.0% |
| 2020 Q2 | 40.88 Thousand SEK | -0.28% |
| 2020 Q1 | 41 Thousand SEK | 0.0% |
| 2020 FY | 442.98 Thousand SEK | 0.0% |
| 2020 Q3 | 443 Thousand SEK | 983.53% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 FY | - SEK | 100.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2018 FY | -450.01 Thousand SEK | 57.11% |
| 2017 FY | -1.04 Million SEK | -132.86% |
| 2016 FY | -450.56 Thousand SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Acarix AB (publ) | 6.83 Million SEK | 99.883% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 99.993% |
| ADDvise Group AB (publ) | 121.2 Million SEK | 99.993% |
| Arcoma AB | 28.02 Million SEK | 99.971% |
| Bactiguard Holding AB (publ) | 29.64 Million SEK | 99.973% |
| BICO Group AB (publ) | 493.1 Million SEK | 99.998% |
| Boule Diagnostics AB (publ) | 62.4 Million SEK | 99.987% |
| CellaVision AB (publ) | 126.03 Million SEK | 99.994% |
| Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | 99.869% |
| Chordate Medical Holding AB (publ) | 1.77 Million SEK | 99.548% |
| C-Rad AB (publ) | 64.09 Million SEK | 99.988% |
| Duearity AB (publ) | 4.15 Million SEK | 99.808% |
| Dignitana AB (publ) | 7.41 Million SEK | 99.892% |
| Episurf Medical AB (publ) | 3.7 Million SEK | 99.784% |
| Getinge AB (publ) | 6.41 Billion SEK | 100.0% |
| Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 100.475% |
| Iconovo AB (publ) | -4.86 Million SEK | 100.165% |
| Integrum AB (publ) | 22.36 Million SEK | 99.964% |
| Mentice AB (publ) | 14.1 Million SEK | 99.943% |
| OssDsign AB (publ) | 4.3 Million SEK | 99.814% |
| Paxman AB (publ) | 19.99 Million SEK | 99.96% |
| Promimic AB (publ) | 330 Thousand SEK | 97.576% |
| Qlife Holding AB (publ) | 7.29 Million SEK | 99.89% |
| SciBase Holding AB (publ) | 11.91 Million SEK | 99.933% |
| ScandiDos AB (publ) | 22.69 Million SEK | 99.965% |
| Sectra AB (publ) | 36.59 Million SEK | 99.978% |
| Sedana Medical AB (publ) | 42.97 Million SEK | 99.981% |
| Senzime AB (publ) | 20.34 Million SEK | 99.961% |
| SpectraCure AB (publ) | 1.00 SEK | -799900.0% |
| Stille AB | 66.55 Million SEK | 99.988% |
| Vitrolife AB (publ) | 413 Million SEK | 99.998% |
| Xvivo Perfusion AB (publ) | 141.6 Million SEK | 99.994% |